rs780096 — GCKR GCKR Metabolic Balance Variant

GCKR rs780096 — The Enhancer Allele Behind the Glucokinase Trade-Off

Glucokinase regulatory protein (GCKRP), encoded by GCKR on chromosome 2, acts as a brake on hepatic glucokinase — the enzyme that drives the liver's glucose uptake after meals. The rs780096 variant sits within an intronic enhancer that controls how much GCKRP the liver produces. The G allele of rs780096 anchors the CGG haplotype¹¹ CGG haplotype
Three-SNP cluster spanning rs780094, rs780095, rs780096 — all in strong linkage disequilibrium within a short intronic region of GCKR, which drives higher FOXA2-dependent GCKR transcription in liver cells. The C allele forms the TAC haplotype, which produces less GCKRP and therefore exerts a weaker brake on hepatic glucokinase — contributing to the same glucose-lowering, triglyceride-raising metabolic pattern seen across the GCKR locus.

This is a regulatory variant. Unlike the well-characterized rs1260326 Pro446Leu²² rs1260326 Pro446Leu
Coding missense variant in GCKR that directly reduces GCKRP's sensitivity to fructose-6-phosphate, leaving glucokinase constitutively more active variant that acts by reducing the GCKRP protein's inhibitory function, rs780096 modulates the amount of GCKRP produced. The two variants are not in perfect LD — rs780096 captures an independent layer of GCKR regulation.

The Mechanism

A 2017 Genome Medicine study³³ 2017 Genome Medicine study
López Rodríguez, Kaminska et al., Kaikkonen and Laakso groups, University of Eastern Finland mapped a liver-specific transcriptional enhancer in the GCKR intron containing rs780094, rs780095, and rs780096. The CGG haplotype (G at rs780096) showed approximately twofold higher transcriptional activity in luciferase reporter assays and displayed elevated H3K27Ac histone marks — a hallmark of active enhancer chromatin. FOXA2, a liver-enriched transcription factor critical for hepatic glucose and lipid homeostasis, bound this region in a haplotype-specific manner (CGG > TAC), and CRISPR-based epigenetic activation of the enhancer directly increased endogenous GCKR transcript levels. Human liver biopsies confirmed the CGG haplotype transcribes more GCKR RNA in vivo.

The metabolic logic follows from this: more GCKRP (CGG/G allele) means a stronger brake on glucokinase during fasting, keeping hepatic glucose uptake lower and fasting glucose somewhat higher while reducing the lipogenic flux that generates triglycerides. Less GCKRP (TAC/C allele) means a weaker brake, allowing more glucokinase activity, lower fasting glucose, and — through increased glycolytic flux, malonyl-CoA, and citrate production — elevated de novo lipogenesis⁴⁴ de novo lipogenesis
The liver's conversion of carbohydrate precursors into fatty acids and VLDL-triglycerides.

The four-SNP haplotype incorporating rs1260326 (P446L) paints the full picture: CGGC haplotype (G at rs780096, C at rs1260326 = ancestral Pro446) = maximum GCKRP expression with functional inhibitory protein; TACT haplotype (C at rs780096, T at rs1260326 = Leu446) = reduced GCKRP expression plus a less effective inhibitory protein. These two changes compound each other at the locus.

The Evidence

The primary mechanistic evidence for rs780096's enhancer role comes from López Rodríguez et al. 2017, which used luciferase assays, CRISPR activation, and human liver biopsy data to establish the CGG haplotype's regulatory effect. Effect magnitude⁵⁵ Effect magnitude
The paper reports ~twofold or greater transcriptional activity for CGG vs TAC in HepG2 and primary hepatocytes; FOXA2 co-transfection amplified the difference.

The metabolic phenotype evidence comes from studies of the tightly linked rs780094 and rs1260326, which co-segregate on the same TACT haplotype as the rs780096 C allele. The ARIC Study (n=14,889)⁶⁶ ARIC Study (n=14,889)
Atherosclerosis Risk in Communities Study; Köttgen et al. 2010 quantified per-allele effects of the lipogenic GCKR haplotype: −1.93 mg/dl fasting glucose (P=2.3×10⁻⁷), +0.16 mmol/l triglycerides (P=2.4×10⁻³¹), −0.45 HOMA-IR (P=2.2×10⁻⁹), and +0.56 mg/l CRP (P=1.6×10⁻⁸) in white participants. Sparsø et al. 2008 in 16,853 Danes found fasting triglyceride elevation (P=6×10⁻¹⁴) and reduced insulinaemia⁷⁷ fasting triglyceride elevation (P=6×10⁻¹⁴) and reduced insulinaemia
Linked to the same lipogenic GCKR haplotype with modestly reduced T2D risk.

Gene-diet interactions at the GCKR locus are well documented. Tam et al. 2015⁸⁸ Tam et al. 2015
Study of 660 healthy adolescents; nutrition assessed by food frequency questionnaire found that high fish consumption (rich in omega-3) significantly reduced triglycerides in carriers of the lipogenic GCKR allele. Perez-Martinez et al. 2011⁹⁹ Perez-Martinez et al. 2011
LIPGENE dietary cohort, n=379 metabolic syndrome subjects; plasma omega-3 PUFA measured showed the GCKR risk allele group were "high responders" to omega-3: elevated plasma omega-3 reduced fasting insulin (P=0.019), HOMA-IR (P=0.008), and CRP (P=0.032) selectively in risk allele carriers, suggesting omega-3 supplementation is particularly effective for this genotype.

Practical Actions

The C allele at rs780096 contributes to the same GCKR lipogenic phenotype as the T allele at rs780094 and rs1260326: reduced GCKRP output lowers the brake on hepatic glucokinase, channelling more glucose carbon into fat synthesis. Dietary fructose restriction is the most mechanistically targeted response, since fructose bypasses the rate-limiting phosphofructokinase step and floods the hepatic lipogenic pathway that becomes overactive when GCKRP levels are low. Omega-3 fatty acids (EPA and DHA) suppress VLDL-triglyceride secretion and de novo lipogenesis transcriptionally, and gene-diet interaction data specifically supports their benefit in GCKR risk allele carriers. Fasting triglyceride monitoring provides early warning of worsening lipid profiles before cardiovascular or hepatic risk accumulates.

Interactions

rs780096 is part of a four-SNP haplotype with rs780094, rs780095, and rs1260326 (P446L). The C allele at rs780096 co-segregates with the T allele at rs780094 and rs1260326 on the TACT/lipogenic haplotype. Individuals carrying the C allele here very frequently also carry the T (lipogenic) allele at rs780094 — these variants are not perfectly correlated, but their functional effects compound. The strongest documented gene-gene interaction at this locus is with PNPLA3 rs738409 (G allele): dual carriers of the GCKR lipogenic allele and the PNPLA3 NAFLD allele carry substantially higher hepatic steatosis burden than either alone. The GCK promoter variant rs1799884 interacts with GCKR rs780094 on fasting plasma glucose in Chinese populations; a similar compound effect likely applies to rs780096 C allele carriers.